Other: Ofatumumab ( DrugBank: Ofatumumab )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 5 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05266469 (ClinicalTrials.gov) | May 1, 2022 | 23/2/2022 | Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf | Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf Region | Relapsing Multiple Sclerosis | Other: Ofatumumab;Other: Ocrelizumab | Novartis Pharmaceuticals | NULL | Not yet recruiting | 18 Years | 100 Years | All | 240 | NULL | |
| 2 | NCT05090033 (ClinicalTrials.gov) | April 30, 2022 | 22/9/2021 | Characterizing the Use of Ofatumumab in a Real World Setting | Secondary Use of Data Study Characterizing Kesimpta (Ofatumumab) Onboarding and Utilization in RMS Patients Using MSGo, With a Non-interventional Primary Use of Data Sub-study Comparing Patient Reported Outcomes Relative to Clinical Outcomes (EAFToS) | Relapsing Multiple Sclerosis | Other: ofatumumab | Novartis Pharmaceuticals | NULL | Not yet recruiting | 18 Years | N/A | All | 3500 | NULL | |
| 3 | NCT05285904 (ClinicalTrials.gov) | March 30, 2022 | 8/3/2022 | Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study | Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS) | Multiple Sclerosis | Other: Ofatumumab | Novartis Pharmaceuticals | NULL | Not yet recruiting | 18 Years | 99 Years | All | 149 | NULL | |
| 4 | NCT04926818 (ClinicalTrials.gov) | October 5, 2021 | 14/6/2021 | Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis | A 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Siponimod Versus Fingolimod in Pediatric Patients With Multiple Sclerosis Followed by an Open-label Extension | Multiple Sclerosis (MS) | Drug: Fingolimod;Drug: Ofatumumab;Drug: Siponimod;Other: Fingolimod placebo;Other: Siponimod placebo;Other: Ofatumumab placebo | Novartis Pharmaceuticals | NULL | Recruiting | 10 Years | 17 Years | All | 180 | Phase 3 | United States;Australia;Austria;Belgium;France;Germany;India;Latvia;Mexico;Poland;Portugal;Russian Federation;Slovakia;Spain;Turkey |
| 5 | NCT04847596 (ClinicalTrials.gov) | May 21, 2021 | 14/4/2021 | A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab | An Open-label Multicenter Single-arm Pilot Study to Assess Immune Response to COVID-19 Vaccine in Participants With Relapsing Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously | Relapsing Multiple Sclerosis | Other: Ofatumumab;Other: Covid-19 vaccine | Novartis Pharmaceuticals | NULL | Recruiting | 18 Years | 55 Years | All | 22 | United States;Puerto Rico |